Skip to main content
Fig. 1 | Translational Neurodegeneration

Fig. 1

From: Precision medicine in Parkinson’s disease patients with LRRK2 and GBA risk variants – Let’s get even more personal

Fig. 1

Precision medicine in current and future drug trials. a Current precision medicine-based therapies rely on adjusting the hyperactive LRRK2 and hypoactive GBA in PD patients with risk variants of LRRK2 and GBA. b Several poorly understood factors including the putative disease-triggers, genes/environment, the immune system and functional differences among risk variants, may be necessary for developing more efficient and personalized therapies. c It is also possible that idiopathic PD patients with the same imbalances in LRRK2 and GBA as in LRRK2-PD and GBA-PD may benefit from a combinational treatment of both LRRK2 and GBA modulation

Back to article page

Translational Neurodegeneration

ISSN: 2047-9158

Contact us